Investors new

Investors

Overview

Kanabo Group Plc is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing Medical Cannabis Products. The company’s core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Kanabo is currently undertaking a pilot scheme, which will continue for a period of up to 3 months following Admission. The purpose of the Pilot is to measure a number of key performance indicators in relation to the sale of its Retail CBD Products, including consumer preferences, demands for Retail CBD Products, the effectiveness of the supply chain and compliance with quality controls.

The Company has had a 40% customer retention rate since the inception of the Pilot. The second phase will be aimed at delivering growth in sales of Kanabo’s Retail CBD Products.

Kanabo’s future strategy involves continued research and development activities to develop a range of Unlicensed Medical Cannabis Oils, which will be sold alongside its vaporisation device, the VapePod Medical. It is intended that Unlicensed Medical Cannabis Oils will be sold as unlicensed medicines in the UK and Germany.

IR announcements

Corporate Governance

The Directors are committed to maintaining high standards of corporate governance, and propose, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.

The Board has established Board Committees for Audit, Remuneration and Nominations and is committed to developing further policies and procedures which reflect the principles of good governance.

The Company has adopted a share dealing code for the Directors and will take steps to ensure compliance by the Directors and any relevant employees with the terms of this code.

The Directors have established financial controls and reporting procedures which are considered appropriate given the size of and structure of the Company. These controls will continue to be reviewedas the Company develops and will be revised accordingly.

Professional Advisors

Public Relations

RKM Communications Ltd

Work.Life
Waverley House
9 Noel Street
London W1F 8GQ

Reporting Accountant and Auditor

Jeffreys Henry Finsgate

5-7 Cranwood Street
London EC1V 9EE

Investor Relations

VOX Markets

1 PoultryLondon EC2R 8EJ

Capital Structure & Shareholder Information

Total issued and outstanding 422,916,056

 

Directors
Shareholdings
Percentage shareholding fully diluted Number of Options
Avihu Tamir 21.24% 0
David Tsur 2.48% 2,700,000
Daniel Poulter 0.68% 3,600,000
Andy Morrison 1.46% 900,000
Gil Efron 0.34% 1,800,000

 

Significant Shareholders Percentage shareholding
fully diluted
David Sack 3.54%

 

Other Equity Instruments
Significant Shareholders Percentage shareholding fully diluted
Deferred Consideration based on milestones 38,461,492.00
Employees Option – exercise price 16.5p 2,700,000.00
Employees Option – exercise price 27.21p 4,000,000.00
Employees Option – exercise price 2.5p 3,239,672.00
Employees Option – exercise price 6.5p/8p 13,854,400.00
Employees Option – exercise price 12.65p 2,437,628.00
Employees Option – exercise price 10.15p 975,527.00
Previous directors – exercise price 2.5p/10p 1,800,000.00
Warrants – exercise price 10p 2,928,779.00
Warrants – exercise price 6.5p 2,701,719.00
Warrants – exercise price 5p 1,150,000.00
Warrants – exercise price 16p 14,062,500.00
Warrants – exercise price 24p 14,062,500.00

General Information

Kanabo Group Plc
(Incorporated in England and Wales with Registered No. 10485105)
The Company is subject to the UK City Code on Takeovers and Mergers

Registered Office Address:
Churchill House
137-139 Brent Street
London
NW4 4DJ